Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Kinarus Therapeutics logo — Kinarus Therapeutics is a clinical-stage company developing...

Kinarus Therapeutics

Kinarus Therapeutics is a clinical-stage company developing therapies for viral, respiratory and ocular diseases.

Founded 2017 Switzerland Basel, Switzerland 5 employees Post-IPO Equity Total: $36.55M Biopharma, Biotechnology +2

General Information

Company Name Kinarus Therapeutics
Founded Year 2017
Location Switzerland Basel, Switzerland
Employees 5
Industries Biopharma, Biotechnology, Health Care +1
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Kinarus Therapeutics. To contact Kinarus Therapeutics, visit kinarus.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Kinarus Therapeutics compare?

A PDF of Kinarus Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Kinarus Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Kinarus Therapeutics

Kinarus Therapeutics is a clinical-stage pharmaceutical company based in Switzerland. Established in 2017, the company is dedicated to developing innovative treatments for viral, respiratory, and ophthalmic diseases. Their flagship drug candidate is an oral combination of a P38 mitogen-activated protein kinase (p38 MAPK) inhibitor, acquired from Roche, and a second drug, designed to provide long-term effective treatment. Kinarus is currently conducting a significant Phase 2 clinical trial for hospitalized Covid-19 patients, aiming to reduce mortality and duration of hospital stay. The novel drug candidate addresses viral replication, inflammation, and organ damage. Additionally, they have secured regulatory approval for a one-year Phase 2 clinical trial for wet Age-Related Macular Degeneration, a condition often undertreated despite available therapies. Their innovative drug, administered alongside existing anti-VEGF agents, holds the potential to reduce injection frequency and offer enhanced therapeutic benefits. In terms of funding, Kinarus Therapeutics recently received a Fr.1.50M post-IPO equity investment on 11 May 2023 from Chaodian Culture, signifying continued investor confidence in the company's mission and potential. With a focus on critical healthcare needs and promising treatment approaches, Kinarus Therapeutics is a compelling player in the biopharma and biotechnology industries, positioning itself as a noteworthy venture for potential investors.

Business keywords: clinical-stage pharmaceutical company, drug development, viral diseases, respiratory diseases, ophthalmic diseases, p38 MAPK inhibitor, Covid-19 treatment, Phase 2 clinical trial, Age-Related Macular Degeneration, VEGF inhibitors, regulatory approval, patient-focused treatments, Switzerland-based company, Roche collaboration, hospitalized patients

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity Fr.1.50M 1
Chaodian Culture
11 May 2023
Post IPO Equity Fr.20.00M 1
Yorkville Advisors
Yorkville Advisors
22 Aug 2022
Grant Fr.7.00M -
13 Dec 2021
Series B Fr.3.35M -
01 Sep 2021
Convertible Note Fr.700.00K -
12 Aug 2018
Seed Round Fr.4.00M -
11 Jan 2018

Kinarus Therapeutics Alternatives & Competitors

View All Alternatives
Kinarus Therapeutics vs
Molecure
Molecure Poland

Fate can be altered.

Post-IPO Secondary
85 employees
Biopharma, Biotechnology
Compare Kinarus Therapeutics vs Molecure
Kinarus Therapeutics vs
InterCure
InterCure

Harness the power of respiratory-based treatment for hypertension and heart failure with innovative...

Post-IPO Equity
Biotechnology, Health Care
Kinarus Therapeutics vs
X4 Pharmaceuticals
X4 Pharmaceuticals United States

Enabling a better future for people with rare immune disorders

Post-IPO Debt
137 employees
Biotechnology, Health Care
View all alternatives

FAQ About Kinarus Therapeutics

Kinarus Therapeutics is a clinical-stage company developing therapies for viral, respiratory and ocular diseases.
Kinarus Therapeutics was founded in 2017.
Kinarus Therapeutics is headquartered in Basel, Switzerland.
Kinarus Therapeutics operates in Biopharma, Biotechnology, Health Care and Life Sciences. Its work centres on clinical-stage pharmaceutical company, drug development, viral diseases and respiratory diseases.
Kinarus Therapeutics has approximately 5 employees.
Kinarus Therapeutics has completed 6 funding rounds, raising a total of $36.55M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Kinarus Therapeutics include Molecure, InterCure, X4 Pharmaceuticals, Antios Therapeutics, MethylGene. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Kinarus Therapeutics and Molecure are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Kinarus Therapeutics, https://bouncewatch.com/company/kinarus-therapeutics, updated 12 September 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout